These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
151 related articles for article (PubMed ID: 9033261)
21. Clinical utility of human glandular kallikrein 2 within a neural network for prostate cancer detection. Stephan C; Jung K; Soosaipillai A; Yousef GM; Cammann H; Meyer H; Xu C; Diamandis EP BJU Int; 2005 Sep; 96(4):521-7. PubMed ID: 16104903 [TBL] [Abstract][Full Text] [Related]
22. Preoperative blood reverse transcriptase-PCR assays for prostate-specific antigen and human glandular kallikrein for prediction of prostate cancer progression after radical prostatectomy. Shariat SF; Gottenger E; Nguyen C; Song W; Kattan MW; Andenoro J; Wheeler TM; Spencer DM; Slawin KM Cancer Res; 2002 Oct; 62(20):5974-9. PubMed ID: 12384565 [TBL] [Abstract][Full Text] [Related]
23. Identification of human glandular kallikrein hK2 from LNCaP cells. Grauer LS; Charlesworth MC; Saedi MS; Finlay JA; Liu RS; Kuus-Reichel K; Young CY; Tindall DJ J Androl; 1996; 17(4):353-9. PubMed ID: 8889697 [TBL] [Abstract][Full Text] [Related]
24. Detection of circulating prostate cells by reverse transcriptase-polymerase chain reaction of human glandular kallikrein (hK2) and prostate-specific antigen (PSA) messages. Corey E; Arfman EW; Oswin MM; Melchior SW; Tindall DJ; Young CY; Ellis WJ; Vessella RL Urology; 1997 Aug; 50(2):184-8. PubMed ID: 9255285 [TBL] [Abstract][Full Text] [Related]
25. Detection of human glandular kallikrein, hK2, as its precursor form and in complex with protease inhibitors in prostate carcinoma serum. Grauer LS; Finlay JA; Mikolajczyk SD; Pusateri KD; Wolfert RL J Androl; 1998; 19(4):407-11. PubMed ID: 9733142 [TBL] [Abstract][Full Text] [Related]
26. Immunohistochemical localization of human kallikreins 6, 10 and 13 in benign and malignant prostatic tissues. Petraki CD; Gregorakis AK; Papanastasiou PA; Karavana VN; Luo LY; Diamandis EP Prostate Cancer Prostatic Dis; 2003; 6(3):223-7. PubMed ID: 12970725 [TBL] [Abstract][Full Text] [Related]
27. Insulin-like growth factor binding proteins (IGFBPs) as potential physiological substrates for human kallikreins hK2 and hK3. Réhault S; Monget P; Mazerbourg S; Tremblay R; Gutman N; Gauthier F; Moreau T Eur J Biochem; 2001 May; 268(10):2960-8. PubMed ID: 11358513 [TBL] [Abstract][Full Text] [Related]
28. Characterization and processing of prostate specific antigen (hK3) and human glandular kallikrein (hK2) secreted by LNCaP cells. Väisänen V; Lövgren J; Hellman J; Piironen T; Lilja H; Pettersson K Prostate Cancer Prostatic Dis; 1999 Mar; 2(2):91-97. PubMed ID: 12496845 [TBL] [Abstract][Full Text] [Related]
29. The value of (-7, -5)pro-prostate-specific antigen and human kallikrein-2 as serum markers for grading prostate cancer. Bangma CH; Wildhagen MF; Yurdakul G; Schröder FH; Blijenberg BG BJU Int; 2004 Apr; 93(6):720-4. PubMed ID: 15049979 [TBL] [Abstract][Full Text] [Related]
30. The role of human glandular kallikrein 2 for prediction of pathologically organ confined prostate cancer. Haese A; Graefen M; Becker C; Noldus J; Katz J; Cagiannos I; Kattan M; Scardino PT; Huland E; Huland H; Lilja H Prostate; 2003 Feb; 54(3):181-6. PubMed ID: 12518322 [TBL] [Abstract][Full Text] [Related]
31. Molecular genetic profiling of Gleason grade 4/5 prostate cancers compared to benign prostatic hyperplasia. Stamey TA; Warrington JA; Caldwell MC; Chen Z; Fan Z; Mahadevappa M; McNeal JE; Nolley R; Zhang Z J Urol; 2001 Dec; 166(6):2171-7. PubMed ID: 11696729 [TBL] [Abstract][Full Text] [Related]
33. Kallikrein 4 (hK4) and prostate-specific antigen (PSA) are associated with the loss of E-cadherin and an epithelial-mesenchymal transition (EMT)-like effect in prostate cancer cells. Veveris-Lowe TL; Lawrence MG; Collard RL; Bui L; Herington AC; Nicol DL; Clements JA Endocr Relat Cancer; 2005 Sep; 12(3):631-43. PubMed ID: 16172196 [TBL] [Abstract][Full Text] [Related]
34. Long-term prediction of prostate cancer up to 25 years before diagnosis of prostate cancer using prostate kallikreins measured at age 44 to 50 years. Lilja H; Ulmert D; Björk T; Becker C; Serio AM; Nilsson JA; Abrahamsson PA; Vickers AJ; Berglund G J Clin Oncol; 2007 Feb; 25(4):431-6. PubMed ID: 17264339 [TBL] [Abstract][Full Text] [Related]
35. Association of kallikrein expression in nipple aspirate fluid with breast cancer risk. Sauter ER; Lininger J; Magklara A; Hewett JE; Diamandis EP Int J Cancer; 2004 Feb; 108(4):588-91. PubMed ID: 14696124 [TBL] [Abstract][Full Text] [Related]
36. Identification of a novel complex between human kallikrein 2 and protease inhibitor-6 in prostate cancer tissue. Mikolajczyk SD; Millar LS; Marker KM; Rittenhouse HG; Wolfert RL; Marks LS; Charlesworth MC; Tindall DJ Cancer Res; 1999 Aug; 59(16):3927-30. PubMed ID: 10463585 [TBL] [Abstract][Full Text] [Related]
37. Screening for prostate cancer in 2008 II: the importance of molecular subforms of prostate-specific antigen and tissue kallikreins. Jansen FH; Roobol M; Jenster G; Schröder FH; Bangma CH Eur Urol; 2009 Mar; 55(3):563-74. PubMed ID: 19058905 [TBL] [Abstract][Full Text] [Related]
38. The role of molecular forms of prostate-specific antigen (PSA or hK3) and of human glandular kallikrein 2 (hK2) in the diagnosis and monitoring of prostate cancer and in extra-prostatic disease. Becker C; Noldus J; Diamandis E; Lilja H Crit Rev Clin Lab Sci; 2001 Oct; 38(5):357-99. PubMed ID: 11720279 [TBL] [Abstract][Full Text] [Related]
39. The role of P501S and PSA in the diagnosis of metastatic adenocarcinoma of the prostate. Sheridan T; Herawi M; Epstein JI; Illei PB Am J Surg Pathol; 2007 Sep; 31(9):1351-5. PubMed ID: 17721190 [TBL] [Abstract][Full Text] [Related]